Atlas Trials

Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy

Clinical trial NCT04263610 · COMPLETED

Trial details

NCT number
NCT04263610
Sponsor
Almirall, S.A.
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Plaque Psoriasis
Start date
2019-09-04
Primary completion
2022-02-16
Enrollment
190

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.